Literature DB >> 827405

The heterocytotoxicity of human serum. III. Studies of the serum levels and distribution of activity in human populations.

G Glumac, A Mates, D Eidinger.   

Abstract

A metabolic inhibition assay has been employed to investigate the distribution of serum heterocytotoxicity mediated by natural antibody activating the classical complement pathway and by antibody-independent activation of the alternative complement pathway in human serum samples derived from various groups of individuals. Levels in female cancer patients and in women taking oral contraceptives were significantly elevated over normal controls. Newborn infants exhibited approximately half of the average adult levels. Levels were maximally elevated in patients with visceral cancer, particularly in individuals with adenocarcinomas, while patients with sarcomas exhibited reduced levels. These and other data derived from the literature suggest that the metabolic inhibition assay may provide a useful measure of natural antibody and activation of the alternate complement pathway representative of mechanisms of natural immunity vs tumours.

Entities:  

Keywords:  Antibodies--analysis; Biology; Cancer; Cervical Cancer; Clinical Research; Contraception; Contraceptive Methods--side effects; Diseases; Family Planning; Hematological Effects; Hemic System; Immunity; Immunoglobulin Alterations; Immunologic Factors; Neoplasms; Oral Contraceptives--side effects; Physiology; Research Methodology

Mesh:

Substances:

Year:  1976        PMID: 827405      PMCID: PMC1540972     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Inhibitory effect of guinea pig serum on a number of new leukaemias in mice.

Authors:  E A BOYSE; L J OLD; E STOCKERT
Journal:  Nature       Date:  1963-05-25       Impact factor: 49.962

2.  VARIATIONS IN THE ONCOLYTIC ACTIVITY OF HUMAN SERUM.

Authors:  F HARTVEIT
Journal:  Acta Pathol Microbiol Scand       Date:  1964

3.  Investigations of the influence of sera from pregnant women on the growth of cell cultures in conjunction with the occurrence of abnormal alpha-lipoprotein.

Authors:  J REJNEK; T BEDNARIK; E RERABKOVA; A DOLEZAL
Journal:  Clin Chim Acta       Date:  1963-01       Impact factor: 3.786

4.  Further experiments concerning the lytic power of blood serum against ascites tumor cells.

Authors:  R WILLHEIM; E REVICI; P FLUSS; M AUBER
Journal:  Exp Med Surg       Date:  1959

5.  Growth-controlling action of human serum in cell culture.

Authors:  K PENTTINEN; E SAXEN
Journal:  Nature       Date:  1959-11-14       Impact factor: 49.962

6.  The mechanism of cytolysis of Ehrlich ascites tumour brought into contact with normal human serum.

Authors:  M KURU; G KOSAKI; H ITOUZI; H ISIBASI; A TOKUNAGA
Journal:  Acta Unio Int Contra Cancrum       Date:  1959

7.  The action of cytotoxic antisera on the HeLa strain of human carcinoma.

Authors:  D G MILLER; T C HSU
Journal:  Cancer Res       Date:  1956-05       Impact factor: 12.701

8.  Characterization of the natural hemagglutinins in normal rat serum associated with a negative phase following tumor implantation.

Authors:  P M APTEKMAN; A E BOGDEN
Journal:  Cancer Res       Date:  1956-03       Impact factor: 12.701

9.  Properdin system and immunity. II. Interaction of the properdin system with polysaccharides.

Authors:  L PILLEMER; M D SCHOENBERG; L BLUM; L WURZ
Journal:  Science       Date:  1955-09-23       Impact factor: 47.728

10.  Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance.

Authors:  J D BROOME
Journal:  J Exp Med       Date:  1963-07       Impact factor: 14.307

View more
  1 in total

1.  Tumour cell conditioned medium reveals greater M2 skewing of macrophages in the absence of properdin.

Authors:  Izzat A M Al-Rayahi; Michael J Browning; Cordula Stover
Journal:  Immun Inflamm Dis       Date:  2017-01-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.